Diagonal Bio AB (publ) ("Diagonal Bio" or "the Company") today announces that Stall Courant, based in Heby, and one of Sweden’s leading international horse trotting and breeding stables, has placed an order for LAMPLify. The stable is managed by the internationally renowned trotting trainer Sabine Kagebrant and home to more than 125 horses. Stall Courant has chosen a 36-month leasing agreement through Svea Bank, which shows both confidence in the technology and a long-term commitment. The order follows the successful completion of the pilot test, which began in March 2025 and includes the purchase of LAMPlify along with associated consumables.
Order from Stall Courant
Stall Courant is a leading international horse trotting stable and operates a dedicated breeding program. It was founded in 2005, based in Heby, owned by Unibet’s founder Anders Ström and managed by Sabine Kagebrant, an internationally renowned trotting trainer. The stable is renowned for its focus on high-quality horses and strong international presence in France and the United States. Over the years, Stall Courant has established itself as a trusted and influential name in global harness racing.
"We travel a lot with our horses, both nationally and internationally. We have evaluated the LAMPlify solution and appreciate that we now get rapid and accurate results that enables us to take swift actions to ensure the wellbeing of our horses.” – Sabine Kagebrant, CEO of Stall Courant
“We are very pleased that Stall Courant, following a successful trial period, has now decided to move forward with an order. This is an important confirmation that LAMPlify delivers the value and accurate test results we promise. We look forward to further developing our collaboration with Stall Courant and building a long-term relationship that creates value for both parties.” - Karin Wehlin, CEO of Diagonal Bio AB (publ)
For additional information about Diagonal Bio, please contact:
Karin Wehlin, CEO
Phone: +46 70 305 24 88
E-mail: kw@diagonalbio.com
About Diagonal Bio
Diagonal Bio AB was founded in 2020 and is a Swedish biotechnology company with headquarters and offices in Lund. The Company develops the PANVIRAL® platform to detect and diagnose small sections of pathogen genomes, for example viruses, bacteria and fungi. The Company was founded with the goal of reducing human suffering by revolutionising global diagnostics of pathogen-borne diseases with proprietary technology. Diagonal Bio's patented technology can also be used for the less regulated market segments via LAMPlify®.